May 09,2023

Sanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users

DarioHealth announced today the presentation of research at ISPOR 2023 demonstrating significant reductions in healthcare resource utilization for Dario users with type 2 diabetes compared to non-users, the first study completed by Sanofi U.S. under its strategic agreement with Dario. This study used de-identified user data from Dario and claims data, through tokenization, to build highly comparable groups through a meticulous matching method that matched 2,445 Dario users with 7,334 non-users. The difference-in-difference method was used to analyze changes between the start and end of the study period in each group and between Dario user and non-user groups, on predefined primary and secondary endpoints. The results demonstrate a statistically significant 9.3% reduction in all-cause Heath Care Resource Utilization (HCRU), including a 23.5% reduction in hospitalizations, in Dario users after 12 months.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
May 09,2023

Study backs Fitterfly digital therapeutic for diabetes management

New research published in JMIR Diabetes demonstrated the real-world effectiveness of the Fitterfly Diabetes digital therapeutic program. The study analyzed de-identified data of 109 participants with type 2 diabetes. The program features three phases. First, it observes participants’ CGM readings for one week. Next, they received diet- and exercise-based interventions through the Fitterfly app and coaches. Finally, researchers tracked whether the participants sustained their new lifestyle modifications over three months. Researchers say about 85% of all participants observed an average reduction of 1.2% in HbA1c levels. The study also found that participants who engaged more with the Fitterfly app presented improved clinical outcomes.

CLINICAL STUDY

#coaching

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
May 09,2023

ASCENSIA DIABETES CARE EXPANDS PAYMENT ASSISTANCE AND SIMPLE SAVINGS PROGRAM FOR EVERSENSE E3 CGM System

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program. Eligibility for the program has now been extended to all commercially insured people with diabetes across the country, including those who do not have coverage for the Eversense E3 system from their insurance provider. Additionally, new Eversense E3 users will now only pay $99 out of pocket for their first two Eversense E3 systems* extending the $99 introductory offer that was previously available for just the initial sensor and smart transmitter. This results in an out-of-pocket cost of less than $200 for an entire year of continuous glucose monitoring with Eversense E3 for new users. For each sensor thereafter, users will pay a maximum of $100 per month, or $600 for the six-month duration of each sensor.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 03,2023

Welldoc Named "Best Overall Digital Health Company" in 7th Annual MedTech Breakthrough Awards Program

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it has been selected as "Best Overall Digital Health Company" in the 7th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market. In 2022, MedTech Breakthrough selected Welldoc as winner of the "Best Overall Connected Healthcare Solution" award.

View Analyst & Ambassador Comments
Go to original news
May 03,2023

Lilly to Participate in Bank of America Securities 2023 Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a fireside chat on Wednesday, May 10 at 1 p.m., Eastern time.

View Analyst & Ambassador Comments
Go to original news
May 03,2023

JDRF Canada launches advocacy campaign for type 1 diabetes device (T1D) access

JDRF Canada is recommending that candidates in the upcoming provincial election support Albertans living with type 1 diabetes (T1D) by expanding coverage of continuous glucose monitors (CGM) devices to all ages. The organization also urges the government to expand coverage to include Flash Glucose Monitoring (Flash GM) devices for all ages.

View Analyst & Ambassador Comments
Go to original news
May 03,2023

Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028

DexCom, Inc. announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the "notes") in a private placement. The notes will be senior, unsecured obligations of Dexcom, and will bear interest at a rate of 0.375% per year, payable semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2023.

FUNDING POST-IPO DEBT
View Analyst & Ambassador Comments
Go to original news
May 03,2023

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

Dexcom announced today the publication of a study "Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK" in Diabetes Therapy. The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits. Based on a willingness-to-pay threshold of £20,000 per quality-adjusted life year (QALY), the research found: 70.8% probability of rtCGM being cost-effective to the NHS compared to finger-pricking to test via a blood glucose meter and; 38.7% probability of rtCGM being cost-saving to the NHS as it can help decrease the risk of developing diabetes-related complications. The estimated yearly cost of diabetes to the NHS in 2022 is £10 billion – around 10% of its budget. rtCGM was associated with An incremental cost-effectiveness ratio of £3,684 per QALY versus testing with finger pricks.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 04,2023

Health Canada licenses Medtronic Guardian 4 CGM sensor for use with MiniMed 780G

Medtronic (NYSE:MDT) announced that it received a license from Health Canada for use of its Guardian 4 with the MiniMed 780G. The licensing enables the use of the next-generation continuous glucose monitor sensor with the next-generation automated insulin pump. MiniMed 780G with Guardian 4, an advanced, hybrid closed-loop system, helps users manage type 1 diabetes.

PRODUCT

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
May 04,2023

DarioHealth to Report First Quarter 2023 Results on Thursday, May 11th

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that it would release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES